David Shaw’s Novavax NVAX Stock Holding History

David Shaw’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.41M	Hold	150,000	–	–	﹤0.01%	3491
2026 Q1	$1.22M	Hold	150,000	–	–	﹤0.01%	3289
2025 Q4	$1.01M	Sell	150,000 -125,000	-45%	-$942K	﹤0.01%	3538
2025 Q3	$2.38M	Hold	275,000	–	–	﹤0.01%	2839
2025 Q2	$1.73M	Buy	+275,000	New	+$1.82M	﹤0.01%	2845
2024 Q1	–	Sell	-60,000	Closed	-$288K	–	4611
2023 Q4	$288K	Sell	60,000 -52,500	-47%	-$321K	﹤0.01%	3760
2023 Q3	$815K	Buy	112,500 +50,000	+80%	+$400K	﹤0.01%	3175
2023 Q2	$464K	Hold	62,500	–	–	﹤0.01%	3450
2023 Q1	$433K	Hold	62,500	–	–	﹤0.01%	3621
2022 Q4	$643K	Sell	62,500 -20,000	-24%	-$353K	﹤0.01%	3715
2022 Q3	$1.5M	Sell	82,500 -29,500	-26%	-$1.28M	﹤0.01%	3255
2022 Q2	$5.76M	Sell	112,000 -251,100	-69%	-$13M	0.01%	1955
2022 Q1	$26.7M	Buy	363,100 +139,700	+63%	+$12.5M	0.03%	841
2021 Q4	$32M	Sell	223,400 -20,000	-8%	-$3.44M	0.03%	789
2021 Q3	$50.5M	Sell	243,400 -49,100	-17%	-$10.8M	0.05%	530
2021 Q2	$62.1M	Buy	292,500 +236,700	+424%	+$43.4M	0.05%	441
2021 Q1	$10.1M	Buy	+55,800	New	+$11.1M	0.01%	1342
2020 Q4	–	Sell	-101,100	Closed	-$11M	–	4094
2020 Q3	$11M	Buy	+101,100	New	+$12.3M	0.01%	1184

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

David Shaw's NVAX Position: Q2 2026 in Review

David Shaw reduced its Novavax (NVAX) stake by 27% in Q2 2026, selling an estimated $18.4M and leaving 5,650,905 shares worth $53.2M. The position accounts for 0.03% of the portfolio, ranked #730.

David Shaw first reported a position in NVAX in Q2 2013 and has held it in 48 quarters since. The position peaked at $82.9M in Q2 2020. 264 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

David Shaw held 5,650,905 shares of Novavax worth $53.2M as of Q2 2026.
David Shaw sold 2,058,953 Novavax shares in Q2 2026, an estimated $18.4M.
Novavax made up 0.03% of David Shaw's portfolio in Q2 2026, its #730 holding.
David Shaw first reported a position in Novavax in Q2 2013 and has held it in 48 quarters since.
David Shaw's Novavax position peaked at $82.9M in Q2 2020.
264 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.